FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094985385> ?p ?o ?g. }

• W3094985385 endingPage "14" @default.
• W3094985385 startingPage "13" @default.
• W3094985385 abstract "Patients with COVID-19 and underlying hematological malignancy seem to have a higher mortality rate compared with those patients without malignancy, however, the extent of such excess risk is unclear. We performed a systematic review of literature and a pooled analysis to provide precise estimates of the mortality rate among patients with both hematological malignancy and COVID-19. Methods: We performed a systematic literature search including peer-reviewed publications, preprints, and conference proceedings up to July 16, 2020. Only studies including exclusively patients with hematological malignancies were considered. The primary endpoint was the case fatality rate (CFR), which was defined as rate of death in patients with hematological malignancy and COVID-19. A random effects model was used to derive a pooled CFR and its 95% confidence interval (CI). Results: In total, 10 studies including 751 patients with both COVID-19 and hematological malignancy were selected for the pooled analysis (Table 1). A total of 257 deaths were recorded in this population. The probability of death was 37·48% (95% CI 27·74% to 48.36%; I2=48·1%) in this patient population (Figure 1). [Data will be updated closer to the ASH 2020 meeting]. Conclusions: Patients with both COVID-19 and hematological malignancy have a higher probability of mortality compared to patients with COVID-19 but without underlying malignancy. Optimally and tailored preventive measures are needed to reduce the risk of COVID-19 infection in patients with hematological malignancies; this patient population should be priority for vaccine campaigns. Figure Disclosures Saini: Covance Inc.: Current Employment; European Commission: Other: Consulting fees. Tagliamento:Roche: Other: Travel grant; Bristol-Myers Squibb: Other: Travel grant; AstraZeneca: Other: Travel grant; Takeda: Other: Travel Grant; Novartis: Honoraria; Amgen: Honoraria. Lambertini:Roche: Other: Consultant; Novartis: Other: Consultant; Roche: Speakers Bureau; Takeda: Speakers Bureau; Lilly: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Speakers Bureau; Theramex: Speakers Bureau. McNally:Covance Inc.: Current Employment. Kelly:Covance Inc.: Current Employment. Romano:Covance Inc.: Current Employment. Chico:Covance Inc.: Current Employment. Jenson:Laboratory Corporation of America: Current Employment. Anderson:Laboratory Corporation of America: Current Employment, Current equity holder in publicly-traded company; OmniSeq: Membership on an entity's Board of Directors or advisory committees. Curigliano:Novartis: Other: personal fees for consulting, advisory role and speakers' bureau ; Pfizer: Other: personal fees for consulting, advisory role and speakers' bureau ; Lilly: Other: personal fees for consulting, advisory role and speakers' bureau ; Foundation Medicine: Other: personal fees for consulting, advisory role and speakers' bureau ; Samsung: Other: personal fees for consulting, advisory role and speakers' bureau ; Daichii-Sankyo: Other: personal fees for consulting, advisory role and speakers' bureau ; Ellipses Pharma: Honoraria; Roche/Genentech: Other: fees for travel and accommodation ; Pfizer: Other: fees for travel and accommodation ; Roche/Genentech: Other: personal fees for consulting, advisory role and speakers' bureau . de Azambuja:Roche/Genentech: Other: honoraria and advisory board fees and travel grant, and research grant to institution; Novartis: Other: honoraria and advisory board fees and travel grant and research grant to institution; Seattle Genetics: Other: honoraria and advisory board fees ; GSK: Other: Travel grant and research grant to institution; AstraZeneca: Other: Research grant to institution." @default.
• W3094985385 created "2020-11-09" @default.
• W3094985385 creator A5003897511 @default.
• W3094985385 creator A5007283699 @default.
• W3094985385 creator A5011860143 @default.
• W3094985385 creator A5016558677 @default.
• W3094985385 creator A5017369626 @default.
• W3094985385 creator A5036201601 @default.
• W3094985385 creator A5045864473 @default.
• W3094985385 creator A5062186554 @default.
• W3094985385 creator A5074054015 @default.
• W3094985385 creator A5082293621 @default.
• W3094985385 creator A5087056344 @default.
• W3094985385 date "2020-11-05" @default.
• W3094985385 modified "2023-09-29" @default.
• W3094985385 title "Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies" @default.
• W3094985385 doi "https://doi.org/10.1182/blood-2020-141749" @default.
• W3094985385 hasPublicationYear "2020" @default.
• W3094985385 type Work @default.
• W3094985385 sameAs 3094985385 @default.
• W3094985385 citedByCount "0" @default.
• W3094985385 crossrefType "journal-article" @default.
• W3094985385 hasAuthorship W3094985385A5003897511 @default.
• W3094985385 hasAuthorship W3094985385A5007283699 @default.
• W3094985385 hasAuthorship W3094985385A5011860143 @default.
• W3094985385 hasAuthorship W3094985385A5016558677 @default.
• W3094985385 hasAuthorship W3094985385A5017369626 @default.
• W3094985385 hasAuthorship W3094985385A5036201601 @default.
• W3094985385 hasAuthorship W3094985385A5045864473 @default.
• W3094985385 hasAuthorship W3094985385A5062186554 @default.
• W3094985385 hasAuthorship W3094985385A5074054015 @default.
• W3094985385 hasAuthorship W3094985385A5082293621 @default.
• W3094985385 hasAuthorship W3094985385A5087056344 @default.
• W3094985385 hasBestOaLocation W30949853851 @default.
• W3094985385 hasConcept C107130276 @default.
• W3094985385 hasConcept C126322002 @default.
• W3094985385 hasConcept C179755657 @default.
• W3094985385 hasConcept C187316915 @default.
• W3094985385 hasConcept C2779134260 @default.
• W3094985385 hasConcept C2779399171 @default.
• W3094985385 hasConcept C2908647359 @default.
• W3094985385 hasConcept C2909984355 @default.
• W3094985385 hasConcept C3008058167 @default.
• W3094985385 hasConcept C44249647 @default.
• W3094985385 hasConcept C524204448 @default.
• W3094985385 hasConcept C71924100 @default.
• W3094985385 hasConcept C95190672 @default.
• W3094985385 hasConcept C99454951 @default.
• W3094985385 hasConceptScore W3094985385C107130276 @default.
• W3094985385 hasConceptScore W3094985385C126322002 @default.
• W3094985385 hasConceptScore W3094985385C179755657 @default.
• W3094985385 hasConceptScore W3094985385C187316915 @default.
• W3094985385 hasConceptScore W3094985385C2779134260 @default.
• W3094985385 hasConceptScore W3094985385C2779399171 @default.
• W3094985385 hasConceptScore W3094985385C2908647359 @default.
• W3094985385 hasConceptScore W3094985385C2909984355 @default.
• W3094985385 hasConceptScore W3094985385C3008058167 @default.
• W3094985385 hasConceptScore W3094985385C44249647 @default.
• W3094985385 hasConceptScore W3094985385C524204448 @default.
• W3094985385 hasConceptScore W3094985385C71924100 @default.
• W3094985385 hasConceptScore W3094985385C95190672 @default.
• W3094985385 hasConceptScore W3094985385C99454951 @default.
• W3094985385 hasIssue "Supplement 1" @default.
• W3094985385 hasLocation W30949853851 @default.
• W3094985385 hasLocation W30949853852 @default.
• W3094985385 hasOpenAccess W3094985385 @default.
• W3094985385 hasPrimaryLocation W30949853851 @default.
• W3094985385 hasRelatedWork W2089684929 @default.
• W3094985385 hasRelatedWork W2098436002 @default.
• W3094985385 hasRelatedWork W2212248987 @default.
• W3094985385 hasRelatedWork W2374200962 @default.
• W3094985385 hasRelatedWork W2378234934 @default.
• W3094985385 hasRelatedWork W2387808676 @default.
• W3094985385 hasRelatedWork W3205821059 @default.
• W3094985385 hasRelatedWork W4221006869 @default.
• W3094985385 hasRelatedWork W4361987285 @default.
• W3094985385 hasRelatedWork W2903040050 @default.
• W3094985385 hasVolume "136" @default.
• W3094985385 isParatext "false" @default.
• W3094985385 isRetracted "false" @default.
• W3094985385 magId "3094985385" @default.
• W3094985385 workType "article" @default.